Corlanor (ivabradine) is not designed to lower blood pressure [1]. Instead, it works by slowing the heart rate [1]. This reduction in heart rate decreases the workload on the heart, which can be beneficial for individuals with heart failure [1].
How does Corlanor work differently from blood pressure medications?
Unlike medications that directly target blood vessels or reduce fluid volume to lower blood pressure, Corlanor acts on the heart's natural pacemaker, the sinoatrial node [1]. By inhibiting the "funny" current (If), it selectively slows down the heart rate without affecting other cardiac functions like blood pressure or contractility to a significant degree [1]. This mechanism is key to its therapeutic effect in certain types of heart failure.
When might Corlanor be prescribed?
Corlanor is typically prescribed for patients with symptomatic chronic heart failure who have a reduced ejection fraction and are in sinus rhythm with a resting heart rate of 70 beats per minute or higher, despite being on maximally tolerated doses of beta-blockers [1]. Its primary goal is to improve symptoms, reduce hospitalizations for heart failure, and decrease the risk of cardiovascular death in these specific patient populations.
What are the potential side effects of Corlanor?
While Corlanor does not directly lower blood pressure, patients may experience side effects such as bradycardia (an abnormally slow heart rate) and visual disturbances, including transient luminous phenomena [1]. Other reported side effects include dizziness, atrial fibrillation, and hypertension [1]. It is important for patients to report any new or worsening symptoms to their healthcare provider.
Who makes Corlanor?
Corlanor is developed and marketed by Amgen [2].